Germline mutations in high penetrance genes are associated with worse clinical outcomes in patients with non–small cell lung cancerCentral MessagePerspective by Seth B. Krantz, MD, Kanwal Zeeshan, MBBS, Kristine M. Kuchta, MS, Thomas A. Hensing, MD, Kathy A. Mangold, PhD, S. Lilly Zheng, MD, Jianfeng Xu, MD, DrPH

Get full text